CREATIVE BIO-PEPTIDES, INC.
RAP-103, a CCR2/CCR5 antagonist peptide therapeutic for synapse loss in Lewy body dementia and mixed-proteinopathy dementias
- Sector
- Biotech
- Total capital
- $9.5M
- Federal grants
- $9.5M
- 10 awards · 2019–2025
- Rank in peer group#59 of 514
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 7
- 30 pending · first 2020
- Rank in peer group#48 of 514
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · A Synapse-Protecting Small Peptide to Treat a-Syn/Tau Mixed Proteinopathies in Alzheimer's Disease Related Dementias (ADRD)$1.1M
- Federal grantHealth and Human S · Phase II · A Synapse-Protecting Small Peptide to Treat a-Syn/Tau Mixed Proteinopathies in Alzheimer's Disease Related Dementias (ADRD)$1.4M
- Federal grantHealth and Human S · Phase I · PET Imaging to Evaluate a Novel Chemokine Antagonist to Protect Synapses in ADRD$175K
- Federal grantHealth and Human S · Phase I · PET Imaging to Evaluate a Novel Chemokine Antagonist to Protect Synapses in ADRD$325K
- Federal grantHealth and Human S · Phase II · Development of a Novel Chemokine Receptor Antagonist as a Treatment for Opioid Use Disorder$1.1M
- Federal grantHealth and Human S · Phase II · Development of a Novel Chemokine Receptor Antagonist as a Treatment for Opioid Use Disorder$1.2M
- Federal grantHealth and Human S · Phase II · Development of a Novel Chemokine Receptor Antagonist Peptide as a Non-Opioid Treatment for Relief of Chronic Pain$3M
Show 3 earlier federal awards
- Federal grantHealth and Human S · Phase I · Optimization of a Chemokine Receptor Antagonist Peptide as a Synapse Protecting Treatment for Neurodegeneration in Alzheimer's Disease$500K
- Federal grantHealth and Human S · Phase I · Development of a Novel Chemokine Receptor Antagonist Peptide as a Synapse Protecting Treatment for Neurodegeneration in Alzheimer's Disease$449K
- Federal grantHealth and Human S · Phase I · A Novel Chemokine Receptor Antagonist to Block Opioid Reinforcement, Relapse and Physical Dependence$322K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#59 · top 11%
- Granted patents#48 · top 9%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 7 granted of 37- GrantedUse of an All-D-Pentapeptide Chemokine Antagonist to Reduce Opioid Dose in a Person with PainUSPTOUS RE50,630
- GrantedUse of an All-D-Pentapeptide Chemokine Antagonist to Reduce Opioid Dose in a Person with PainUSPTOUS RE50,563
- PendingCompositions and Methods for Treating NeuropathyUSPTOApplication 18559874
Show all 37 patent records
- Use of an All-D-Pentapeptide Chemokine Antagonist to Reduce Opioid Dose in a Person with PainOct 14, 2025 · US RE50,630Granted
- Use of an All-D-Pentapeptide Chemokine Antagonist to Reduce Opioid Dose in a Person with PainSep 2, 2025 · US RE50,563Granted
- Compositions and Methods for Treating NeuropathyJun 19, 2025 · Application 18559874Pending
- Methods and Compositions for Use of a Chemokine Receptor Antagonist Peptide to Treat Addiction, Substance Abuse Disorders or Symptoms ThereofJun 19, 2025 · Application 19053588Pending
- Methods and Compositions for Use of a Chemokine Receptor Antagonist Peptide to Treat Addiction, Substance Abuse Disorders or Symptoms ThereofMar 25, 2025 · US 12,257,283Granted
- Compositions and Methods for Treating Persistent Postsurgical PainAug 1, 2024 · Application 18560768Pending
- Oral Peptide Antagonists Of Multiple Chemokine Receptors For Reversing Loss Of Synapses And Dendritic SpinesJul 18, 2024 · Application 18512201Pending
- Methods and Compositions for Use of a Chemokine Receptor Antagonist Peptide to Treat Addiction, Substance Abuse Disorders or Symptoms ThereofNov 29, 2022 · US 11,510,961Granted
- Oral Peptide Antagonists Of Multiple Chemokine Receptors For Reversing Loss Of Synapses And Dendritic SpinesAug 12, 2021 · Application 17170790Pending
- Therapeutic Peptides And VaccinesApr 13, 2021 · US 10,973,906Granted
- Anti-inflammatory Peptides For Treating Non-alcoholic Steatohepatitis (nash)Apr 21, 2020 · US 10,624,944Granted
- Use Of An All-D-Pentapeptide Chemokine Antagonist To Reduce Opioid Dose In A Person With PainApr 21, 2020 · US 10,624,945Granted
- Oral Anti-inflammatory Peptides To Treat Epilepsy, Seizures And Cns DisordersJan 24, 2019 · Application 16038144Pending
- Topically Active Peptides For Treating Cosmetic And Dermatological ConditionsDec 6, 2018 · Application 15989823Pending
- Use Of An All-d-pentapeptide Chemokine Antagonist To Reduce Opioid Dose In A Person With PainApplication 17869925Pending
- Compositions And Methods For Treating Persistent Postsurgical PainApplication PCTUS2022032835Pending
- Compositions And Methods For Treating NeuropathyApplication PCTUS2022030305Pending
- Compositions and Methods for Treating and Preventing Persistent Postsurgical Pain (PPSP)Application 63208517Pending
- Treatments for Opioid-Induced Respiratory DepressionApplication 19486605Pending
- Peptides for Diabetic Painful NeuropathyApplication 63191010Pending
- Oral Anti-inflammatory Peptides To Treat Epilepsy, Seizures And Cns DisordersApplication PCTUS2019040977Pending
- Anti-inflammatory Peptides For Treating Non-alcoholic Steatohepatitis (nash)Application PCTUS2019037627Pending
- Use of an All-D-Pentapeptide Chemokine Antagonist to Reduce Opioid Dose in a Person with PainApplication 19213362Pending
- Peptides for Treating Neurological DisordersApplication 19153409Pending
- Peptides And Therapies For Treating Neurological DisordersApplication PCTUS2025029579Pending
- Peptides and Therapies for Treating Neurological DisordersApplication 63764624Pending
- Peptides and Therapies for Treating Neurological DisordersApplication 63734988Pending
- Peptides and Therapies for Treating Neurological DisordersApplication 63724155Pending
- Peptides and Therapies for Treating Neurological DisordersApplication 63688931Pending
- Treatments For Opioid-induced Respiratory DepressionApplication PCTUS2024030461Pending
- Peptides and Therapies for Treating Neurological DisordersApplication 63648204Pending
- Peptides For Treating Neurological DisordersApplication PCTUS2024014413Pending
- Peptides for Treating Neurological DisordersApplication 63603774Pending
- Treatments for Opioid-Induced Respiratory DepressionApplication 63522191Pending
- Treatments for opioid-induced respiratory depressionApplication 63468291Pending
- Peptides for Treating Neurological DisordersApplication 63443497Pending
- Use of an All-D-Pentapeptide Chemokine Antagonist to Reduce Opioid Dose in a Person with PainApplication 17816448Pending
Related companies, and why
- VilyaSimilar federal contract value in Biotech · null in contracts
- Biotherapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- NOARA THERAPEUTICS CORP.Similar federal contract value in Biotech · null in contracts
- REALSEQ BIOSCIENCES, INC.Similar federal contract value in Biotech · null in contracts
- CRYPTYX BIOSCIENCE, INC.Similar federal contract value in Biotech · null in contracts
- MAMMAE BIOSCIENCES, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .